ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
Open Access
- 21 July 2015
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 26 (4) , 921-931
Abstract
Objectives To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases. Conclusions The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. Key points • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.Keywords
This publication has 53 references indexed in Scilit:
- Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesionsBMC Medical Imaging, 2013
- Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CTBritish Journal of Radiology, 2012
- Diagnostic Challenges and Pitfalls in MR Imaging with Hepatocyte-specific Contrast AgentsRadioGraphics, 2011
- A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findingsMagnetic Resonance Imaging, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Comparison of Portal Venous and Delayed Phases of Gadolinium-Enhanced Magnetic Resonance Imaging Study of Cirrhotic Liver for the Detection of Contrast Washout of Hypervascular Hepatocellular CarcinomaJournal of Computer Assisted Tomography, 2010
- Gadoxetate Disodium–Enhanced MRI of the Liver: Part 1, Protocol Optimization and Lesion Appearance in the Noncirrhotic LiverAmerican Journal of Roentgenology, 2010
- Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial ExperienceKorean Journal of Radiology, 2010
- Superparamagnetic Iron Oxide-Enhanced Liver Magnetic Resonance ImagingInvestigative Radiology, 2006
- Estimating the reliability of continuous measures with cronbach's alpha or the intraclass correlation coefficient: Toward the integration of two traditionsJournal of Clinical Epidemiology, 1991